Investigational Drug Details
| Drug ID: | D177 |
| Drug Name: | Hydroxy citric acid |
| Synonyms: | 2-hydroxy-1,2,3-propanetricarboxyic acid; 2-Hydroxytricarballylic acid; 3-carboxy-3-hydroxypentane-1,5-dioic acid; Anhydrous citric acid; Citric acid monoglyceride; Citric acid, anhydrous; Citric acid,anhydrous |
| Type: | Chemical drug |
| DrugBank ID: | DB04272 |
| DrugBank Description: | A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability. Citric acid was one of active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020. |
| PubChem ID: | 22230 |
| CasNo: | 5949-29-1 |
| Repositioning for NAFLD: | Yes |
| SMILES: | O.C(CC(=O)O)(CC(=O)O)(C(=O)O)O |
| Structure: |
|
| InChiKey: | YASYEJJMZJALEJ-UHFFFAOYSA-N |
| Molecular Weight: | 210.138 |
| DrugBank Targets: | Fumarate hydratase class II inhibitor; 6-phosphogluconolactonase; L-amino-acid oxidase; Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1; Cytochrome c peroxidase; Hepatocyte growth factor-regulated tyrosine kinase substrate; Inv |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | PGLS; HGS; CS; RTCA; CS; APRT; LYZ |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Clinical trial on-going (IRCT201503273320N11) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0870 | IRCT201503273320N11 | Not applicable | Not Recruiting | No Results Available | 27/07/2015 | 18 June 2018 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A19457 | 26557974 | Iran J Basic Med Sci | Effect of pioglitazone, quercetin and hydroxy citric acid on extracellular matrix components in experimentally induced non-alcoholic steatohepatitis. | Details |
| A19891 | 26281317 | Turk J Med Sci | Effect of pioglitazone, quercetin, and hydroxy citric acid on vascular endothelial growth factor messenger RNA (VEGF mRNA) expression in experimentally induced nonalcoholic steatohepatitis (NASH). | Details |
| A21440 | 25317811 | Eur Rev Med Pharmacol Sci | Pioglitazone, quercetin and hydroxy citric acid effect on cytochrome P450 2E1 (CYP2E1) enzyme levels in experimentally induced non alcoholic steatohepatitis (NASH). | Details |
| A22184 | 24761121 | Pharmacognosy Res | Pioglitazone, quercetin and hydroxy citric acid effect on hepatic biomarkers in Non Alcoholic Steatohepatitis. | Details |
| A22393 | 24622831 | J Physiol Pharmacol | Comparative effect of pioglitazone, quercetin and hydroxy citric acid on the status of lipid peroxidation and antioxidants in experimental non-alcoholic steatohepatitis. | Details |
| A50367 | 35416190 | Food Funct | The effect of hydroxy citric acid supplementation with calorie-restricted diet on metabolic, atherogenic and inflammatory biomarkers in women with non-alcoholic fatty liver disease: a randomized controlled clinical trial. | Details |